Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New fingerprick test and antibiotic aim to stop leprosy before it starts

NCT ID NCT06222372

Prevention Sponsor: Annemieke Geluk Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study in Bangladesh tests whether giving a single dose of the antibiotic rifampin to people who live with or near leprosy patients can prevent infection. Researchers will use a new fingerprick blood test to measure infection markers before and after treatment. The goal is to find an easy way to stop leprosy from spreading.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rifampin (antibiotic)
What this could lead to
If successful, this could provide a simple way to identify and treat people at risk of leprosy before they develop the disease, helping to stop its spread.
What could go wrong
This is an early-stage study focused on measuring infection markers, not preventing disease directly. The test and treatment may not work as hoped in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2020

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria patients: \- newly diagnosed multibacillary leprosy patients (BI 1-6) Inclusion Criteria contacts of MB leprosy patients: * living in the same house (household members) * living in a house on the same compound * sharing the same kitchen * direct neighbors (first neighbors) * willing to participate * provide informed consent Exclusion Criteria patients: * refusal of examination of their contacts * suffering from the pure neural form of leprosy * residing only temporarily in the study area * PB leprosy patients Exclusion Criteria contacts: * diagnosed as leprosy patients during contact examination * living less than 100 m away from a patient already included in the study * first and second degree relatives of a patient already included in the study * refusal informed consent * pregnancy * tuberculosis or leprosy treatment * below 5 years of age * known to suffer from liver disease or jaundice * residing temporarily in the study area

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Leprosy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multibacillary leprosy leprosy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leprosy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Leprosy Mission International - Bangladesh

    RECRUITING

    Nilphamari, 5300, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.